{"entity":{"id":"biomerieux","kind":"company","name":"bioMérieux","aka":["bioMerieux"],"tldr":"French in vitro diagnostics company, best known for infection testing, whose THxID BRAF kit was a companion diagnostic for melanoma drugs.","summary":"bioMérieux describes itself as a world leader in in vitro diagnostics and dates its history to 1963 and the Mérieux family; its press releases are datelined Marcy-l'Étoile, France. Most of its products test for infections. In oncology its US arm held the approval for the THxID BRAF Kit (2013), a companion diagnostic for dabrafenib, trametinib and later encorafenib with binimetinib in melanoma, which the FDA PMA database records as withdrawn in June 2024.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.biomerieux.com"},{"label":"FDA PMA P120014","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120014"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["diagnostics"],"technologies":["companion-diagnostic"],"targets":[],"drugs":["thxid-braf"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marcy-l'Étoile","country":"FR","companyType":"diagnostics","website":"https://www.biomerieux.com","investors":[],"funding":[]},"route":"/companies/biomerieux/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"drug":[{"id":"thxid-braf","kind":"drug","name":"THxID BRAF Kit","route":"/drugs/thxid-braf/"}]}}